Pharvaris is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases, specifically bradykinin-mediated angioedema. The company’s lead product, deucrictibant, is an oral small-molecule bradykinin B2 receptor antagonist being developed for both the on-demand treatment and long-term prophylaxis of hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH). Deucrictibant is available in two formulations: an immediate-release capsule for acute attack management and an extended-release tablet for daily prophylaxis. The company is conducting global Phase 3 clinical trials and plans to submit a New Drug Application to the U.S. Food and Drug Administration in the first half of 2026. Pharvaris serves patients with rare, potentially life-threatening genetic and acquired conditions characterized by unpredictable swelling episodes. The company was incorporated in 2015 and changed its name from Pharvaris B.V. to Pharvaris N.V. in 2021 in connection with its initial public offering.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage pharvaris.com
Sector Healthcare IR page ir.pharvaris.com/news-events/publications
Tags
rare diseases, bradykinin-mediated angioedema, hereditary angioedema, acquired angioedema, small-molecule drugs, oral therapeutics, bradykinin b2 receptor antagonists, clinical-stage, deucrictibant, PHA-022121, PHA121, PHVS719, PHVS416, RAPIDe-1, RAPIDe-2, RAPIDe-3, CHAPTER-1
Press page —

Metrics

Valuation  
Market cap $ 2.227B
Market cap (USD) $ 2.227B
P/E -10.74
PEG —
P/BV 6.52
P/S —
P/OCF -12.64
P/FCF -12.63
Dividend yield —
Turnover / mcap —
Returns  
ROE -65.2%
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 62
Quality score -80.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Assets 301.455M 291.375M 398.694M 167.733M 212.09M 101.1M 20.598M
Net profit -175.699M -134.222M -100.875M -76.333M -42.7M -25.986M -8.027M
Free cash flow -137.238M -120.668M -93.139M -67.287M -44.73M -21.543M -6.69M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 23.6 17.45 25.77 11.17 12.22 — —
Price performance 12m 0.45 -0.32 1.49 -0.22 — — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Income detail
Research and development expense (EUR) 3.65M 5.68M 19.5M 35.8M 57.4M 65.6M 98.6M 124M
↳ 5y CAGR +78.2% +76.9% +44.9%
Reported Apr 29, 2021 Apr 29, 2021 Apr 29, 2021 Mar 29, 2022 Apr 5, 2023 Apr 10, 2024 Apr 7, 2025 Apr 2, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•Topline data from part 1 of CREAATE, a pivotal Phase 3 study evaluating deucrictibant XR for the prophylaxis of AAE-C1INH attacks, expected in 1Q2027; enrollment ongoing in part 2 of CREAATE evaluating deucrictibant IR for the on-demand treatment of AAE-C1INH attacks

•Preparation of NDA dossier of deucrictibant XR for prophylaxis of AE-BK attacks ongoing; timeline remains on-track for submission in 1H2027

•Strong financial position with cash and cash equivalents of €283 million as of September 30, 2026

ZUG, Switzerland, November 12, 2026 – Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the third quarter ending on September 30, 2026, and provided a business update.

“The successful readout of the pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks was a major milestone for Pharvaris.

October 29, 2026

PDF Version

  • Pivotal, Phase 3 CHAPTER-3 data selected for late-breaking oral presentation on Saturday, November 14

ZUG, Switzerland, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and five abstracts for poster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting, to be held November 12-16, 2026, in Phoenix, Arizona. Among the accepted presentations, data from the pivotal Phase 3 CHAPTER-3 study of oral deucrictibant extended-release tablet for the prophylaxis of HAE attacks will be featured in a late-breaking oral presentation.

Details of the presentations are as follows:

  • **Title:**Early and Sustained Effects of Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks **Presenter:**John Anderson, M.D. **Format:**Poster Presentation **Date, time:**Friday, November 13, 2026, 5:05 p.m. MST (7:05 p.m. EST)

  • **Title:**Economic Burden and Treatment Patterns Among Individuals With Hereditary Angioedema: a U.S. Closed Claims Analysis **Presenter:**Raffi Tachdjian, M.D., MPH **Format:**Poster Presentation **Date, time:**Saturday, November 14, 2026, 12:45 p.m. MST (2:45 p.m. EST)

  • **Title:**Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks: The Phase 3 CHAPTER-3 Trial **Presenter:**Marc A. Riedl, M.D., M.S. **Format:**Oral Presentation **Date, time:**Saturday, November 14, 2026, 5:33 p.m. MST (7:33 p.m. EST)

  • **Title:**Oral Deucrictibant for Prophylaxis of Hereditary Angioedema Attacks: Final Results From the CHAPTER-1 Open-Label Extension **Presenter:**Michael E. Manning, M.D. **Format:**Poster Presentation **Date, time:**Sunday, November 15, 2026, 11:45 a.m. MST (1:45 p.m. EST)

  • **Title:**Clinical Cardiovascular Safety Evaluation of Oral Deucrictibant **Presenter:**Anne Lesage, Ph.D. **Format:**Poster Presentation **Date, time:**Sunday, November 15, 2026, 12:15 p.m. MST (2:15 p.m. EST)

  • **Title:**Evaluation of Safety Margins and Response to Deucrictibant Immediate-Release Capsule Combined With Deucrictibant Extended-Release Tablet **Presenter:**Anne Lesage, Ph.D. **Format:**Poster Presentation **Date, time:**Sunday, November 15, 2026, 12:30 p.m. MST (2:30 p.m. EST)

The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: ir.pharvaris.com/news-events/events-presentations.

About Pharvaris Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. For more information, visit https://pharvaris.com/.

October 8, 2026

PDF Version

  • Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete symptom resolution (11.95 hours)

  • Deucrictibant IR showed a well-tolerated safety profile

  • NDA and MAA of deucrictibant IR for the on-demand treatment of HAE attacks under review by regulatory authorities

ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results of RAPIDe-3, a phase 3, global, randomized, double-blind, placebo-controlled crossover study evaluating oral deucrictibant immediate-release (IR) capsule (20 mg) for the on-demand treatment of HAE attacks in adolescents and adults have been published in The Lancet (Journal Impact Factor: 109.0).

“Bradykinin B2 receptor antagonism is a validated and reliable mechanism currently being widely used for the on-demand treatment of HAE attacks,” said Marc A. Riedl, M.D., M.S., Professor of Medicine, Clinical Director of the U.S. Hereditary Angioedema Association (HAEA) Angioedema Center at the University of California San Diego (UCSD), principal RAPIDe-3 study investigator, and lead Author of the publication. “The results of the RAPIDe-3 study demonstrate that deucrictibant IR, an orally-administered bradykinin B2 receptor antagonist, rapidly ended attack progression and accelerated the time to complete symptom resolution. Publication in The Lancet, one of the world’s highest-impact academic journals, maximizes the visibility of these data to a global network of clinicians, researchers, and patients. If approved, deucrictibant IR will be the first approved oral bradykinin B2 receptor antagonist, with the potential to address unmet needs of people living with HAE by providing reliable symptom relief and resolution with a single convenient oral capsule.”

RAPIDe-3 (NCT06343779) met its primary endpoint and all 11 secondary endpoints with high statistical significance. Deucrictibant IR achieved End of Progression™1 (EoP) of attack symptoms, symptom relief, and complete symptom resolution significantly faster than placebo, with most attacks being adequately controlled with a single capsule. Deucrictibant IR was well tolerated with no safety signals observed. Results were consistent across subgroups of participants defined according to age, geographic location, HAE type (including HAE with normal C1 inhibitor), use of long-term prophylaxis, and attack severity and location (including non-severe laryngeal attacks).

Peng Lu, M.D., Ph.D., President of Pharvaris, added, “the consistent results from RAPIDe-3 across subgroups underscores the clinical relevance of antagonizing the bradykinin B2 receptor, a downstream target that stops the effects of excess bradykinin regardless of the pathways through which it is generated. These findings represent the first pivotal step in Pharvaris’ broader clinical development strategy of investigating deucrictibant across both on-demand and prophylactic settings with the goal of delivering new treatment options that may address unmet medical needs of those living with bradykinin-mediated angioedema.”

The full article can be found here: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01296-1/fulltext

Results of the RAPIDe-3 study are consistent with results of RAPIDe-1, which were published in April 2026 in The Lancet Haematology. An open-label extension study of deucrictibant IR for the on-demand treatment of HAE attacks, RAPIDe-2 (NCT05396105), is ongoing. An expanded access program (EAP) (NCT07759141) for deucrictibant IR for the on-demand treatment of HAE attacks is also available to people in U.S. meeting eligibility requirements.

A New Drug Application (NDA) for deucrictibant IR for the on-demand treatment of HAE attacks is currently under review with the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of April 23, 2027. A Marketing Authorization Application (MAA) for deucrictibant IR for on-demand treatment of HAE attacks is also currently under review with the European Medicines Agency (EMA).


1 The term End of Progression is a registered trademark of Pharvaris GmbH.

About Deucrictibant Deucrictibant is a novel, potent, orally bioavailable small-molecule bradykinin B2 receptor antagonist currently in clinical development. Deucrictibant is being investigated for its potential to prevent the occurrence of bradykinin-mediated angioedema attacks and to treat the manifestations of attacks if/when they occur by inhibiting bradykinin signaling through the bradykinin B2 receptor. Pharvaris is developing two formulations of deucrictibant for oral administration: an extended-release tablet to enable sustained absorption and efficacy as prophylactic treatment, and an immediate-release capsule to enable rapid onset of activity for on-demand treatment. Deucrictibant has been granted orphan drug designation for the treatment of bradykinin-mediated angioedema by the U.S. Food and Drug Administration, the European Commission, and Swissmedic.

About Pharvaris Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. For more information, visit https://pharvaris.com/.

Forward Looking Statements This press release contains certain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements relating to our future plans, studies and trials, and any statements containing the words “believe,” “anticipate,” “expect,” “estimate,” “may,” “could,” “should,” “would,” “will” and similar expressions. These forward-looking statements are based on management’s current expectations, are neither promises nor guarantees, and involve known and unknown risks, uncertainties and other important factors that may cause Pharvaris’ actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements. Such risks include but are not limited to the following: uncertainty in the outcome of our interactions with regulatory authorities, including the FDA; the expected timing, progress, or success of our clinical development programs, especially for deucrictibant immediate-release capsules and deucrictibant extended-release tablets, which are in late-stage global clinical trials; the outcome of regulatory approvals, including the outcome of our NDA and MAA for the on-demand treatment of acute attacks of HAE; our ability to replicate the efficacy and safety demonstrated in the RAPIDe-1, RAPIDe-2, RAPIDe-3, CHAPTER-1, and CHAPTER-3 Phase 2 and Phase 3 studies in ongoing and future nonclinical studies and clinical trials, such as CREAATE; risks arising from epidemic diseases, which may adversely impact our business, nonclinical studies, and clinical trials; our ability to potentially use deucrictibant for alternative purposes, for example to treat C1-INH deficiency (AAE-C1INH); the value of our ordinary shares; the timing, costs and other limitations involved in obtaining regulatory approval for our product candidates, or any other product candidate that we may develop in the future; our ability to establish commercial capabilities or enter into agreements with third parties to market, sell, and distribute our product candidates; our ability to compete in the pharmaceutical industry, including with respect to existing therapies, emerging potentially competitive therapies and with competitive generic products; our ability to market, commercialize and achieve market acceptance for our product candidates; our ability to produce sufficient amounts of drug product candidates for commercialization; our ability to raise capital when needed and on acceptable terms; regulatory developments in the United States, the European Union and other jurisdictions; our ability to protect our intellectual property and know-how and operate our business without infringing the intellectual property rights or regulatory exclusivity of others; our ability to manage negative consequences from changes in applicable laws and regulations, including tax laws (including the Biosecure Act), our ability to maintain an effective system of internal control over financial reporting; changes and uncertainty in general market conditions; disruptions at the FDA and other agencies; changes and uncertainty in general market, political and economic conditions, including as a result of inflation and geopolitical conflicts; changes in regulations and customs, tariffs and trade barriers; and the other factors described under the headings “Cautionary Statement Regarding Forward-Looking Statements” and “Item 3. Key Information—D. Risk Factors” in our Annual Report on Form 20-F and other periodic filings with the U.S. Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. While Pharvaris may elect to update such forward-looking statements at some point in the future, Pharvaris disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Pharvaris’ views as of any date subsequent to the date of this press release.

Prompts

Pharvaris N.V. (ticker PHVS), listed in United States.

ETFs Holding Pharvaris N.V.

ETF Weight in ETF Shares Market value As of
CORO 0.00% 20,508 $ 665.288K Nov 16, 2026